Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC-Specific Chimeric Antigen Receptor

American Journal of Transplantation

Volumn 17, Issue 4, 2017, Pages 917-930

  Noyan, F ^a   Zimmermann, K ^a   Hardtke Wolenski, M ^a   Knoefel, A ^a   Schulde, E ^a   Geffers, R ^b   Hust, M ^c   Huehn, J ^b   Galla, M ^a   Morgan, M ^a   Jokuszies, A ^a   Manns, M P ^a   Jaeckel, E ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

Author keywords

basic (laboratory) research science; gene therapy; immunobiology; immunosuppression immune modulation; T cell biology; tissue (nonvascularized) transplantation; tolerance; tolerance: experimental; translational research science

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; HLA A2 ANTIGEN; INTERLEUKIN 2 RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL CELL; ARTICLE; CELL KILLING; DNA METHYLATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HYBRIDOMA; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SKIN ALLOGRAFT; ALLOGRAFT; ANIMAL; GRAFT SURVIVAL; IMMUNOLOGY; NONOBESE DIABETIC MOUSE; TRANSPLANTATION TOLERANCE;

ALLOGRAFTS; ANIMALS; GRAFT REJECTION; GRAFT SURVIVAL; HLA-A2 ANTIGEN; HUMANS; MICE; MICE, INBRED NOD; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE;

EID: 85011961772     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.14175     Document Type: Article

References (40)

1. Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol 2012; 12: 417–430.
2. Taubert R, Pischke S, Schlue J, et al. Enrichment of regulatory T cells in acutely rejected human liver allografts. Am J Transplant 2012; 12: 3425–3436.
3. Taubert R, Danger R, Londono MC, et al. Hepatic infiltrates in operational tolerant patients after liver transplantation show enrichment of regulatory T cells before proinflammatory genes are down-regulated. Am J Transplant 2016; 16: 1285–1293.
4. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003; 9: 1144–1150.
5. Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008; 14: 88–92.
6. Lee K, Nguyen V, Lee KM, Kang SM, Tang Q. Attenuation of donor-reactive T cells allows effective control of allograft rejection using regulatory T cell therapy. Am J Transplant 2014; 14: 27–38.
7. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T cells in vivo: New answers to an old question. J Immunol 2001; 166: 973–981.
8. Dijke IE, Weimar W, Baan CC. Regulatory T cells after organ transplantation: Where does their action take place? Hum Immunol 2008; 69: 389–398.
9. Issa F, Hester J, Milward K, Wood KJ. Homing of regulatory T cells to human skin is important for the prevention of alloimmune-mediated pathology in an in vivo cellular therapy model. PLoS ONE 2012; 7: e53331.
10. Jaeckel E, von Boehmer H, Manns MP. Antigen-specific FoxP3-transduced T-cells can control established type 1 diabetes. Diabetes 2005; 54: 306–310.
11. Tarbell KV, Yamazaki S, Olson K, Toy P, Steinman RM. CD25+ CD4+ T Cells, expanded with dendritic cells presenting a single autoantigenic peptide. Suppress autoimmune diabetes. J Exp Med 2004; 199: 1467–1477.
12. Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004; 199: 1455–1465.
13. Noyan F, Lee YS, Zimmermann K, et al. Isolation of human antigen-specific regulatory T cells with high suppressive function. Eur J Immunol 2014; 44: 2592–2602.
14. Sagoo P, Ali N, Garg G, Nestle FO, Lechler RI, Lombardi G. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med 2011;3:83ra42.
15. Tsang JY, Tanriver Y, Jiang S, et al. Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice. J Clin Invest 2008; 118: 3619–3628.
16. Juvet SC, Whatcott AG, Bushell AR, Wood KJ. Harnessing regulatory T cells for clinical use in transplantation: The end of the beginning. Am J Transplant 2014; 14: 750–763.
17. Todo S, Yamashita K, Goto R, et al. A pilot study of operational tolerance with a regulatory T cell-based cell therapy in living donor liver transplantation. Hepatology 2016; 64: 632–643.
18. Siepert A, Ahrlich S, Vogt K, et al. Permanent CNI treatment for prevention of renal allograft rejection in sensitized hosts can be replaced by regulatory T cells. Am J Transplant 2012; 12: 2384–2394.
19. Golshayan D, Jiang S, Tsang J, Garin MI, Mottet C, Lechler RI. In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. Blood 2007; 109: 827–835.
20. Gross G, Gorochov G, Waks T, Eshhar Z. Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity. Transplant Proc 1989; 21(1 Pt 1): 127–130.
21. Chmielewski M, Hombach AA, Abken H. Antigen-specific T-cell activation independently of the MHC: Chimeric antigen receptor-redirected T cells. Front Immunol 2013; 4: 371.
22. Galla M, Schambach A, Falk CS, et al. Avoiding cytotoxicity of transposases by dose-controlled mRNA delivery. Nucleic Acids Res 2011; 39: 7147–7160.
23. Schreiber L, Pietzsch B, Floess S, et al. The Treg-specific demethylated region stabilizes Foxp3 expression independently of NF-kappaB signaling. PLoS ONE 2014; 9: e88318.
24. Aichinger M, Wu C, Nedjic J, Klein L. Macroautophagy substrates are loaded onto MHC class II of medullary thymic epithelial cells for central tolerance. J Exp Med 2013; 210: 287–300.
25. Gonzalez-Galarza FF, Takeshita LY, Santos EJ, et al. Allele frequency net 2015 update: New features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res 2015;43(Database issue):D784–D788.
26. Watkins NA, Brown C, Hurd C, Navarrete C, Ouwehand WH. The isolation and characterisation of human monoclonal HLA-A2 antibodies from an immune V gene phage display library. Tissue Antigens 2000; 55: 219–228.
27. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013; 3: 388–398.
28. Floess S, Freyer J, Siewert C, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007; 5: e38.
29. Long SA, Cerosaletti K, Bollyky PL, et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 2010; 59: 407–415.
30. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725–733.
31. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509–1518.
32. Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 2015; 21: 581–590.
33. Rappl G, Schmidt A, Mauch C, Hombach AA, Abken H. Extensive amplification of human regulatory T cells alters their functional capacities and targets them to the periphery. Rejuvenation Res 2008; 11: 915–933.
34. Putnam AL, Safinia N, Medvec A, et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am J Transplant 2013; 13: 3010–3020.
35. Zhou X, Bailey-Bucktrout SL, Jeker LT, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009; 10: 1000–1007.
36. Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA. Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol 2009; 21: 281–285.
37. Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X, et al. Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 2013; 39: 949–962.
38. Bluestone JA, Buckner JH, Fitch M, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med 2015: 7: 315ra189.
39. Elinav E, Adam N, Waks T, Eshhar Z. Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology 2009; 136: 1721–1731.
40. MacDonald KG, Hoeppli RE, Huang Q, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest 2016; 126: 1413–1424.